Please login to the form below

Not currently logged in

NDA Group appoints Bill Griffiths as general manager, UK

He also becomes vice president of the consultancy's advisory board

NDA Group has appointed Bill Griffiths as general manager of its UK team and vice president of its advisory board.

Based in Leatherhead, Surrey, Griffiths will be responsible for managing the European regulatory affairs and patient safety consultancy's business in the UK with effect from 1 March.

He will also be responsible for managing the development, operations and strategy of the firm's advisory board, working closely with the board's regulatory director Steffen Thristrup and NDA Group's scientific director Markku Toivonen.

Griffiths brings nearly 30 years of pharmaceutical experience to the role, having held senior positions at GlaxoSmithKline, Pfizer and Solvay Pharmaceuticals.

He joins the consultancy from Abbott Pharmaceuticals, where he served in Basel as its divisional vice president of global regulatory affairs.

In that role, Griffiths oversaw the regulatory function of the Europe, Latin America, Asia Pacific, India and Japan teams, the company's labeling and advertising promotion, policy and intelligence and quality systems teams as well as a specialist influenza vaccines unit.

Johan Stromquist, NDA Group's chief executive officer, said: “The UK consulting team is NDA's largest team and one of the most important business units for NDA. Identifying an individual with the right background, skillset and experience to support our experienced team and client base has been a challenge.

“I am therefore delighted to bring Bill on board. He brings a fantastic background with both strong pharmaceutical expertise, coupled with outstanding team management - key criteria for driving our UK operations forward.”

24th February 2016

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....